Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Lars Erichsen
Faster-Acting Insulin Aspart Provides Faster Onset and Greater Early Exposure vs Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
Pediatric Diabetes
Internal Medicine
Pediatrics
Endocrinology
Perinatology
Child Health
Metabolism
Diabetes
Related publications
Fiasp: A New Faster-Acting Insulin Aspart Formulation for Diabetes
Prescriber
Pharmacology
The Association Between Anti‐insulin Aspart Antibodies and the Pharmacokinetic and Pharmacodynamic Characteristics of Fast‐acting Insulin Aspart in Children and Adolescents With Type 1 Diabetes
Pediatric Diabetes
Internal Medicine
Pediatrics
Endocrinology
Perinatology
Child Health
Metabolism
Diabetes
Comparison of a Soluble Co-Formulation of Insulin Degludec/Insulin Aspart vs Biphasic Insulin Aspart 30 in Type 2 Diabetes: A Randomised Trial
European Journal of Endocrinology
Medicine
Endocrinology
Metabolism
Diabetes
Use of Short-Acting Insulin Aspart in Managing Older People With Diabetes
Clinical Interventions in Aging
Medicine
Gerontology
Geriatrics
A Survey of Physician Experience and Treatment Satisfaction Using Fast-Acting Insulin Aspart in People With Type 1 or Type 2 Diabetes
Postgraduate Medicine
Medicine
Continuous Subcutaneous Insulin Infusion (CSII) of Insulin Aspart Versus Multiple Daily Injection of Insulin Aspart/Insulin Glargine in Type 1 Diabetic Patients Previously Treated With CSII
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
Use of Fast‐acting Insulin Aspart in Insulin Pump Therapy in Clinical Practice
Diabetes, Obesity and Metabolism
Internal Medicine
Endocrinology
Metabolism
Diabetes
Safety, Immunogenicity and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People With Diabetes Also Using Insulin Glargine: 12-Month Results From the GEMELLI 1 Trial
Diabetes Technology and Therapeutics
Medicine
Endocrinology
Medical Laboratory Technology
Metabolism
Diabetes
15 Years of Experience With Biphasic Insulin Aspart 30 in Type 2 Diabetes
Drugs in R and D
Pharmacology
